| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1b/2 topline data readout example | TTI-101 Hepatocellular carcinoma (HCC) — advanced/relapsed/refractory HCC (Phase 1b/2 REVERT Liver Cancer study) | Phase 1b/2 | — | Small Molecules | - | ||
Phase 1b/2 topline data readout example | TTI-101 Hepatocellular carcinoma (HCC) — advanced/relapsed/refractory HCC (Phase 1b/2 REVERT Liver Cancer study) | Phase 1b/2 | — | Small Molecules | - | ||
Phase 1b/2 topline data readout example | TTI-101 Hepatocellular carcinoma (HCC) — advanced/relapsed/refractory HCC (Phase 1b/2 REVERT Liver Cancer study) | Phase 1b/2 | — | Small Molecules | - |
Recent Updates
Recently added Catalysts
Cara Therapeutics, Inc.$15.96
-0.21 (-1.3%)
C 43Pipeline Score Fair Value Biotech · Clinical
Market Cap
25.44 M
EPS
-15.55
P/E Ratio
-
Value Trade
1.28 M
10.14 %
Week
5.14 %
1 Month
12 %
3 Month
70.51 %
6 Month
-96.84 %
5 Year
-96.18 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
79.05 K
52 Week Range
2.71 - 13.80
% held by Insiders
35.17 %
% held by Institutions
28.85 %
Enterprise Value
25.73 M
Total Shares
4.57 M
Short %
7.17 %
Float Shares
3.90 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
C43
Pipeline Score $73M
Pipeline ValueFair Value
Valuation Signal3
Drugs Scored2.9x
rNPV / MCap Top 63%
Micro Cap (rank 336 of 905)
Percentile RankCara Therapeutics, Inc. carries a moderate pipeline score (43/100), with $3.7B risk-adjusted pipeline value, led by CR845 in Chronic Kidney Diseases (Phase 2), across $160B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CR845 /kg Small molecule | Uremic Pruritus | Phase 3 | NCT02858726 | 58% | $3.5B | COMPLETED | 1,587 | - | - | Mar 14, 2017 | - | Jul 29, 2020 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CARA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Cara Therapeutics, Inc. (CARA) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
CARA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
CARA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
CARA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
CARA Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
CARA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How CARA ranks across every disease it competes inCompetitive Position is a premium feature
See how CARA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial